Results 101 to 110 of about 1,778,131 (183)

Resection versus preservation of anterior end of middle turbinate in eosinophilic chronic rhinosinusitis

The Egyptian Journal of Otolaryngology
Background Eosinophilic chronic rhinosinusitis (eCRS) is a subtype of chronic rhinosinusitis with nasal polyps (CRSwNP), characterized by significant eosinophilic inflammation, although type 2 eosinophilic inflammation can also be identified in CRS ...
Lana Azad, Muaid I. Aziz Baban, Haval Ahmed Hama, Shang Qaraman Qadir Zangana, Aros Bestun Saeed, Shkar Nawzad Omer, Ahmed Muayad, Hwshyar Ali Ahmed, Goran M. Raouf Abdulqader, Paolo Castelnuovo   +9 more
doaj   +1 more source

Chronic sphenoid rhinosinusitis: management challenge

, 2016
Natamon Charakorn, Kornkiat Snidvongs Department of Otolaryngology Head and Neck Surgery, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand Abstract: Chronic sphenoid rhinosinusitis is a ...
Charakorn N, Snidvongs K
core  

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres, Cristobalina Mayorga, Elizabeth J. Phillips, Adriana Ariza, Annick Barbaud, Patrizia Bonadonna, Mariana Castells, Gülfem Çelik, Knut Brockow, Lene H. Garvey, Inmaculada Doña, Jean‐Christoph Caubet, Francesca Mori, Jason Trubiano, Giorgia Marta, Antonino Romano, Ingrid Terreehorst, Asli Gelincik, Philip H. Li, Vito Sabato   +19 more
wiley   +1 more source

IgE‐Binding Bacterial Components Not Yet Documented in the Allergen Databases and Their Allergenic Mechanisms: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Among bacteria that are associated with the development and/or exacerbation of allergic/atopic diseases, several have been described to produce IgE‐binding components. However, only one bacterial protein, Bac s 1, is currently listed in the official database of the World Health Organization/International Union of Immunological Societies (WHO ...
Uta Jappe, Marua Abu Risha, Ioana Agache, Claus Bachert, Barbara Bröker, Riccardo Castagnoli, Gabriele Gadermaier, Richard E. Goodman, Amir Guemari, Christiane Hilger, Alain Jacquet, Sabine Kespohl, Ludger Klimek, Annette Kuehn, Jonas Lidholm, Vera Mahler, Markus Ollert, Thomas A. Platts‐Mills, Monika Raulf, Peter Schmid‐Grendelmeier, Frieder Schmiedeke, Marianne van Hage, Joana Vitte, Josefina Zakzuk, Anna Pomés   +24 more
wiley   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

Diagnostic Delay in Eosinophilic Granulomatosis With Polyangiitis: Clinical Predictors and Implications for Earlier Recognition

Allergy, EarlyView.
This study aimed to assess diagnostic delay among patients with eosinophilic granulomatosis with polyangiitis (EGPA) and identify clinical characteristics associated with delayed recognition. EGPA diagnosis was delayed by nearly five years from symptom onset in this single‐center cohort.
Vani Mulkareddy, Kalena Liu, Shreya Mandloi, Kelsey Limage, Samuel R. Shing, Gurston G. Nyquist, Jessica Most, David Kennedy, Elina Toskala, Damaris Pena‐Evertz   +9 more
wiley   +1 more source

The Origins of Allergy: An Outside‐In, Bioenergetic Hypothesis

Allergy, EarlyView.
ABSTRACT Allergic disease has risen too rapidly for inherited susceptibility to explain it, and the risk variants so far reported lie in the epithelial barrier and in type‐2 immunity. We propose a five‐layer model in which epithelial barrier and bioenergetic dysfunction may precede and promote type‐2 immune deviation rather than arise solely as its ...
Peter K. Smith, Nicholas P. West, Stanley Du Preez, Hugh A. Sampson, Peter W. Hellings, David Price, Liam O'Mahony, Carina Venter, Cezmi A. Akdis, Gil Yosipovitch   +9 more
wiley   +1 more source

Last station in the eosinophilic asthma with chronic rhinosinusitis and/or nasal polyposis march: Eosinophilic asthma with radiological findings associated with blood eosinophilia

, 2018
Objective: Eosinophilic asthma with chronic rhinosinusitis and/or nasal polyposis (EA-CRS/NP) is a subphenotype of adult-onset eosinophilic asthma. Blood eosinophil levels are shown to be highly elevated in patients with EA-CRS/NP and have potential for ...
Bahcecioglu, Sakine Nazik, NAZİK BAHÇECİOĞLU, SAKİNE, YILMAZ, İNSU, OYMAK, FATMA SEMA, TUTAR, NURİ, TÜRK, MURAT, GÜLMEZ, İNCİ   +6 more
core   +1 more source

Complement–Eosinophil Crosstalk Links Complement Activation to Fibrin Deposition in Eosinophilic Chronic Rhinosinusitis

Allergy, EarlyView.
Ryo Hasegawa, Shigeharu Ueki, Misaki Arima, Shohei Nishiyama, Keinosuke Hizuka, Kohei Tatsumi, Ayako Sawai, Anna Shimizu, Yuki Sonoda, Eiichi Kato, Masanori Kidoguchi, Masafumi Sakashita, Yohei Sato, Atsushi Kato, Bruce K. Tan, Robert C. Kern, Robert P. Schleimer, Shigeharu Fujieda, Yoshimasa Imoto   +18 more
wiley   +1 more source

Clinical Trial: Dupilumab Improves Eosinophilic Oesophagitis Outcomes Versus Placebo Regardless of Comorbidities or Treatment History in a Randomised Clinical Trial

Alimentary Pharmacology &Therapeutics, EarlyView.
Dupilumab improved all histological, symptomatic, and endoscopic outcomes assessed at Week 24 versus placebo in patients with eosinophilic oesophagitis, regardless of demographics, disease characteristics, treatment history, or type 2 inflammatory disease comorbidities.
Evan S. Dellon, Marc E. Rothenberg, Jonathan M. Spergel, Albert J. Bredenoord, Antonella Cianferoni, Changming Xia, Margee Louisias, Allen Radin   +7 more
wiley   +1 more source